RxDoctor Payments Data

Harleen Singh, MD

Family Medicine · Miami Gardens, FLNPI 1013358142

Payments from drug & device makers

$1,285in general payments, 2019–2025

Across 71 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$363
  • Neurocrine Biosciences, Inc.$182
  • GSK$126
  • Lilly USA, LLC$110
  • Lundbeck LLC$95
  • AstraZeneca$78
  • plus $331 from 9 others

What the payments were for

  • Food & beverage$1,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,285 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,642
Medicare patients
23
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$39,625
JardianceEmpagliflozin19$26,726
OzempicSemaglutide15$22,193
EliquisApixaban14$20,528
JanuviaSitagliptin Phosphate12$18,333
RybelsusSemaglutide14$16,499
Rosuvastatin Calcium172$1,926
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,850
SynthroidLevothyroxine Sodium21$1,634
Amlodipine Besylate214$1,415
Losartan Potassium124$1,070
Atorvastatin Calcium135$900
Metoprolol Succinate66$843
Nifedipine ErNifedipine36$710
Gabapentin33$673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$110$39,62516 claims
Novo NordiskOzempic, Rybelsus$363$38,69229 claims
Boehringer IngelheimJardiance$40$26,72619 claims
PfizerEliquis$43$20,52814 claims
AbbVieSynthroid$18$1,63421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →